Director, Global Value and Health Economics

🕒 il y a 1 jour

🌐 États-Unis, Royaume-Uni – Distant

🇺🇸 États-Unis – Télétravail 🇬🇧 Royaume-Uni – Télétravail

🏄 California, Pennsylvania – Distant

🏄 California – Remote 🔔 Pennsylvania – Remote

💵 $212 000 - $318 000 / an

⏰ Temps Plein

🔴 Expert

👔 Directeur

🦅 Parrain de Visa H1B

Cette entreprise a parrainé des visas H1B par le passé.

👻 Score fantôme 0%

Ce que ça veut dire : la probabilité que personne ne recrute vraiment pour cette offre.Comment le lire : 60 % ou plus, on pense que c'est une offre fantôme. Un score plus bas est moins inquiétant.Comment on la calcule : ancienneté, republications, postes ouverts vs taille de l'équipe, rapidité de clôture, et si le salaire est indiqué.À noter : une estimation à partir de données publiques, pas un jugement sur l'entreprise. De vraies offres peuvent avoir un score élevé, alors prenez-le comme un indice, pas comme un fait.

Postuler Maintenant

Trouver des Emplois à Distance Similaires

Jazz Pharmaceuticals

Site WebLinkedInTous les Emplois

1001 - 5000 employés

Fondée en 2003

🏥 Santé

🏭 Fabrication

🧬 Biotechnologie

Healthcare • Manufacturing • Biotechnology

Jazz Pharmaceuticals est une entreprise biopharmaceutique dédiée au développement de médicaments innovants répondant à des besoins médicaux sérieux non satisfaits. Avec un fort engagement envers la recherche et le développement, Jazz se concentre sur la création de thérapies transformatrices, mettant en avant l'importance de la collaboration, de la diversité et de l'engagement des employés dans ses opérations. L'entreprise est fière de transformer la vie des patients grâce à ses offres de produits significatives et une culture qui favorise l'enthousiasme et la flexibilité.

Description

• Define and execute global and US payer evidence strategies in Oncology • Lead global HEOR activities and strategies in gastroesophageal adenocarcinoma and prepare assets for commercial and reimbursement milestones worldwide • Serve as lead HEOR partner for an Oncology asset’s expanding clinical pipeline and embed payer and HTA requirements into Phase 2 and Phase 3 programs • Serve as designated US HEOR lead, translating access and reimbursement priorities into evidence strategies supporting commercial, Medicare, and Medicaid access • Execute and author AMCP dossiers, US commercial/Medicare budget impact models, and state Medicaid submission packages • Partner with US Payer Field Teams to develop customer-facing economic models, slide decks, and digital tools • Monitor US health policy and prepare evidence roadmaps for value assessments such as ICER reviews and NCCN Evidence Blocks • Collaborate on innovative payment models and value-based contracts • Integrate payer, HTA, and reimbursement evidence requirements into clinical trial protocols • Optimize trial protocols, comparators, inclusion/exclusion criteria, lines of therapy, and payer-recognized endpoints • Integrate PROs, HRQoL, and HCRU measures into pivotal trials • Develop rare disease evidence strategies addressing small samples, heterogeneous presentations, single-arm studies, and surrogate endpoints • Formulate and execute health economic modeling strategies, including CEA, CUA, and BIM • Design and validate adaptable global core economic models for EU/INT HTA submissions and US payer use • Lead global payer evidence assets, including GVDs, SLRs, and global evidence libraries • Co-deliver HTA evidence packages, including ITCs, NMAs, and economic model adaptations, with the EU/INT HEOR team • Design and deliver RWE, natural history, burden-of-illness, treatment-pattern, and comparative-effectiveness studies • Lead HEOR launch readiness, lifecycle management, label expansion, and post-launch evidence programs • Govern IEGP HEOR commitments and align evidence plans with Market Access, Brand Teams, and Medical Affairs • Lead publication strategy, author peer-reviewed manuscripts, and present at scientific and health economic congresses • Mentor junior scientists, cross-functional colleagues, and HEOR fellows • Ensure evidence generation and communications comply with legal, regulatory, and corporate standards

🎯 Exigences

• Required Master’s degree (MSc, MS, MPH, PhD) in Health Economics, Outcomes Research, Pharmacoeconomics, or a closely related quantitative field • Minimum of 7–10 years of experience in HEOR, Global Value, or Health Economics within the biopharmaceutical industry or a top-tier HEOR consulting firm • Deep working knowledge of US managed care archetypes, including commercial health plans, PBMs, Medicare Part B/D, and Medicaid • Thorough familiarity with US payer communication compliance standards, including FDAMA Section 114 and the 21st Century Cures Act • Advanced expertise in health economic modeling, including Markov state-transition models, partitioned survival models, microsimulation, and discrete event simulation • Demonstrated track record partnering with US Payer Field Teams to develop interactive economic models and value presentation tools • Practical understanding of rare disease evidence generation challenges, including small patient samples, registry utilization, natural history studies, external control arms, and orphan drug HTA mechanisms • Proven track record leading HEOR workstreams for global and US launch preparation, lifecycle management, label expansions, and value defense • Demonstrated experience collaborating with Clinical Development and Biostatistics teams on Phase 2/3 study designs, comparator selection, and HEOR/PRO endpoints • Strong understanding of US health policy developments and experience preparing for or responding to value assessment bodies such as ICER • Proven ability to set global and US evidence strategies while directly executing complex deliverables such as AMCP dossiers, GVDs, NMAs, economic models, and RWE protocols • Ability to lead and collaborate cross-functionally across Clinical Development, Medical Affairs, Market Access, Regulatory, and Commercial without formal authority • Experience managing multi-million-dollar research budgets, vendor selection, and external CROs and academic partners • Experience with oncology assets preferred • Launch lead for at least 2 assets as US HEOR lead or country-level HTA lead • Strong peer-reviewed publication record in health economics and outcomes research

🏖️ Avantages

• Discretionary annual cash bonus or incentive compensation • Discretionary equity grants • Medical insurance • Dental insurance • Vision insurance • 401k retirement savings plan • Flexible paid vacation

📊 Vérifiez votre score de CV pour ce poste

Améliorez vos chances d'obtenir un entretien en vérifiant votre score de CV avant de postuler.

Télécharger le CV